Evidence map›Paper›PMID 35894615›Full record

ArticleMicrobiology spectrum2022

Nanopore Sequencing for Characterization of HIV-1 Recombinant Forms.

Mikiko Mori, Hirotaka Ode, Mai Kubota, Yoshihiro Nakata, Takaaki Kasahara, Urara Shigemi, Reiko Okazaki, Masakazu Matsuda, Kazuhiro Matsuoka, Atsuko Sugimoto and 4 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Mikiko MoriClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Hirotaka OdeClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Mai KubotaClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Yoshihiro NakataClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Takaaki KasaharaClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Urara ShigemiClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Reiko OkazakiClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Masakazu MatsudaClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Kazuhiro MatsuokaClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Atsuko SugimotoClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Atsuko HachiyaClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Mayumi ImahashiClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Yoshiyuki YokomakuClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.
Yasumasa IwataniClinical Research Center, National Hospital Organization Nagoya Medical Centergrid.410840.9, Nagoya, Japan.ORCID 0000-0001-9269-4828
National Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High genetic diversity, including the emergence of recombinant forms (RFs), is one of the most prominent features of human immunodeficiency virus type 1 (HIV-1). Conventional detection of HIV-1 RFs requires pretreatments, i.e., cloning or single-genome amplification, to distinguish them from dual- or multiple-infection variants. However, these processes are time-consuming and labor-intensive. Here, we constructed a new nanopore sequencing-based platform that enables us to obtain distinctive genetic information for intersubtype RFs and dual-infection HIV-1 variants by using amplicons of HIV-1 near-full-length genomes or two overlapping half-length genome fragments. Repeated benchmark tests of HIV-1 proviral DNA revealed consensus sequence inference with a reduced error rate, allowing us to obtain sufficiently accurate sequence data. In addition, we applied the platform for sequence analyses of 9 clinical samples with suspected HIV-1 RF infection or dual infection according to Sanger sequencing-based genotyping tests for HIV-1 drug resistance. For each RF infection case, replicated analyses involving our nanopore sequencing-based platform consistently produced long consecutive analogous consensus sequences with mosaic genomic structures consisting of two different subtypes. In contrast, we detected multiple heterologous sequences in each dual-infection case. These results demonstrate that our new nanopore sequencing platform is applicable to identify the full-length HIV-1 genome structure of intersubtype RFs as well as dual-infection heterologous HIV-1. Since the genetic diversity of HIV-1 continues to gradually increase, this system will help accelerate full-length genome analysis and molecular epidemiological surveillance for HIV-1.

Indexed as

HIV-1HIV InfectionsNanopore SequencingGenome, ViralHumansPhylogenyRecombination, GeneticRetrospective StudiesSequence Analysis, DNAdrug resistancedual infectiongenetic diversityHIV-1molecular epidemiologynanopore sequencingrecombinant form

Identifiers

PMID35894615
PMCPMC9431566
OpenAlexW4288066909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.